AKT News

News

Capivasertib Plus Palbociclib and Fulvestrant Demonstrated Safety, Tolerability Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

01/16/2024

Stephanie Holland

Updated phase 1b results from the CAPItello-292 study demonstrated that capivasertib plus palbociclib and fulvestrant was safe and tolerable among heavily pre-treated patients with HR-positive, HER2-negative advanced breast cancer.

Updated phase 1b results from...

01/16/2024

Oncology

News

Addition of Capivasertib to Fulvestrant Improved PFS Across All Key AKT Pathway Alterations Among Patients With HR-Positive, HER2-Negative Breast Cancer

12/19/2023

Allison Casey

According to an exploratory analysis of the CAPItello-291 trial, the benefit to progression-free survival seen with the addition of capivasertib to fulvestrant was consistent among patients with alterations in all 3 key genes within the AKT...

According to an exploratory...

12/19/2023

Oncology

News

Capivasertib Plus Fulvestrant Approved for Patients With HR-Positive, HER2-Negative Breast Cancer

11/20/2023

Stephanie Holland

Based on results from the phase 2 CAPItello-291 study, the FDA has approved capivasertib plus fulvestrant for patients with previously treated HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring one or more...

Based on results from the phase...

11/20/2023

Oncology

News

Capivasertib Plus Fulvestrant Prolonged PFS in HR-Positive, HER2-Negative Advanced Breast Cancer

08/02/2023

Stephanie Holland

Data from a phase 3 trial found that adding capivasertib to fulvestrant significantly prolonged progression-free survival among patients with HR-positive, HER2-negative advanced breast cancer, compared to fulvestrant alone.

Data from a phase 3 trial found...

08/02/2023

Oncology

News

Fulvestrant Plus Capivasertib Extends Survival in ER-Positive, HER2-Negative Breast Cancer

07/05/2022

Derek Cowsert

Study findings suggest fulvestrant plus capivasertib yielded consistently longer OS and PFS among patients with ER-positive, HER2-negative advanced breast cancer.

Study findings suggest...

07/05/2022

Oncology

News

No Benefit Adding Ipatasertib to First-Line Paclitaxel for PIK3CA-Altered TNBC

11/27/2021

IPATunity130 trial data showed that adding ipatasertib to paclitaxel did not improve PFS in patients with PIK3CA/AKT1/PTEN-altered TNBC.

IPATunity130 trial data showed...

11/27/2021

Oncology

News

Capivasertib Plus Paclitaxel Superior to Paclitaxel Alone for Metastatic TNBC

10/19/2020

Capivasertib in combination with paclitaxel yielded longer PFS and OS in patients with metastatic TNBC, particularly those with PIK3CA/AKT1/PTEN-altered tumors.

Capivasertib in combination with...

10/19/2020

Oncology

News

Fulvestrant–Capivasertib Combo Significantly Prolongs Survival in ER-Positive Breast Cancer

02/14/2020

Adding capivasertib to fulvestrant therapy significantly extends PFS over placebo plus fulvestrant in patients with metastatic, ER-positive breast cancer.

Adding capivasertib to...

02/14/2020

Oncology

Recent News

Conference Coverage

Berlrestotug Added to Dostarlimab Demonstrates Antitumor Activity in PD-L1-High Locally Advanced or Metastatic Non-Small Cell Lung Cancer

09/16/2024

Stephanie Holland ;

Results from the phase 2 GALAXIES Lung-201 study show the addition of berlrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.

Results from the phase 2...

09/16/2024

Oncology

FDA Approval

FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors

09/13/2024

Stephanie Holland ;

On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...

On September 12th, 2024, the US...

09/13/2024

Oncology

Conference Coverage

Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers

09/12/2024

Allison Casey ;

According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.

According to results of the...

09/12/2024

Oncology

News

Sacituzumab Govitecan Shows Potential Among Patients With Locally Advanced or Metastatic Urothelial Cancer

09/10/2024

Stephanie Holland ;

According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...

According to results from Cohort...

09/10/2024

Oncology

Conference Coverage

Biomarkers With Alectinib for ALK-Positive Non-Small Cell Lung Cancer

09/10/2024

Allison Casey ;

According to exploratory biomarker analyses from the phase 3 ALINA trial, there was a benefit to disease-free survival with alectinib regardless of EML4-ALK variant among patients with NSCLC.

According to exploratory...

09/10/2024

Oncology

Conference Coverage

Inhaled Corticosteroids to Reduce Radiation-Induced Pneumonitis Among Patients With Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that the addition of inhaled corticosteroids with radiotherapy significantly reduced the incidence of radiation-induced pneumonitis among patients with non-small cell lung cancer.

Results from a phase 2 study...

09/10/2024

Oncology

Conference Coverage

Neoadjuvant Nivolumab Demonstrated Promising Efficacy and Safety Among Patients With High-Risk Early Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.

According to results from the...

09/10/2024

Oncology

Conference Coverage

Zipalertinib Demonstrated Promising Anti-Tumor Activity Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...

According to results from the...

09/10/2024

Oncology

Conference Coverage

Ivonescimab As New First-Line Treatment Option for Patients with PD-L1–Positive, Advanced Non-Small Cell Lung Cancer

09/09/2024

Allison Casey ;

Ivonescimab showed a clinically meaningful and statistically significant improvement to progression-free survival for patients with PD-L1–positive, advanced non-small cell lung cancer, when compared with pembrolizumab.

Ivonescimab showed a clinically...

09/09/2024

Oncology

Conference Coverage

Tifcemalimab Plus Toripalimab Demonstrated Promising Antitumor Activity For Refractory Extensive-Stage Small Cell Lung Cancer

09/09/2024

Stephanie Holland ;

According to phase 1/2 study results, tifcemalimab plus toripalimab showed promising antitumor activity with a manageable safety profile among patients with refractory extensive-stage small cell lung cancer.

According to phase 1/2 study...

09/09/2024

Oncology